Overview

A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia

Status:
Completed

Trial end date:
2008-01-21

Target enrollment:

Participant gender:

Summary

The aim of this Phase III study is to compare the efficacy, safety and tolerability of dutasteride (0.5mg) with placebo for 6 months, in Korean male subjects with androgenetic alopecia in the vertex region, types IIIv, IV and V according to the modified Norwood-Hamilton Classification.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Dutasteride